Diabetes News

Among adults with chronic kidney disease and type 2 diabetes, the mineralocorticoid receptor inhibitor antagonist finerenone reduced the incidence of CV events regardless of CVD status, according to new data from the FIDELIO trial.

The HF benefits observed in adults with type 2 diabetes and atherosclerotic CVD treated with the SGLT2 inhibitor ertugliflozin were greater among those with moderate to high risk for kidney disease.

Linda F. Fried, MD, MPH, FASN, co-chair of ASN Kidney Week Education Committee, discussed data presented at ASN Kidney Week showing finerenone effective in slowing the progression of chronic kidney disease in patients with diabetes.

A model that utilizes health care professionals from multiple specialties improved the physical well-being of adults with diabetes, researchers wrote.

Data show Black adults with type 2 diabetes and moderate chronic kidney disease were significantly less likely to receive a metformin prescription compared with white counterparts under an old FDA serum creatinine-based metformin label.

A group-based intervention that cost $153 per participant reduced the 2-year risk for type 2 diabetes by up to 47%, according to results from a randomized clinical trial published in JAMA Internal Medicine.

Data presented at ASN Kidney Week showed the mineralocorticoid receptor inhibitor antagonist finerenone was effective in reducing cardiac risk and slowing the progression of chronic kidney disease in patients with diabetes.

Kidney Disease: Improving Global Outcomes has published a practice guideline for diabetes management in patients with chronic kidney disease.

Antibodies in adults with diabetes hospitalized with COVID-19 in Italy had a similar positive response to the SARS-CoV-2 spike protein as those without diabetes, according to findings published in Diabetologia.

A panel of 25 physicians from specialties such as primary care, cardiology and endocrinology prioritized and revised recommendations to deintensify routine care in several areas, including diabetes, pain, cancer and heart disease.